SCHEMBL852353

SCHEMBL852353

O=C(O)c1cnccc1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 11/20 0.55
KDM6B O15054 5/20 0.55
ALDH1A1 P00352 4/20 0.55
KDM4E B2RXH2 4/20 0.55
TDP1 Q9NUW8 3/20 0.55
KDM4D Q6B0I6 3/20 0.55
KDM4A O75164 2/20 0.55
MEN1 O00255 2/20 0.55
THRB P10828 2/20 0.55
KMT2A Q03164 2/20 0.55
MAPT P10636 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
CA12 O43570 2/20 0.48
CA7 P43166 2/20 0.48
CA9 Q16790 2/20 0.48
CA14 Q9ULX7 2/20 0.48
NAPRT Q6XQN6 2/20 0.48
HPGD P15428 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30804202 1.00 KDM4C (0.55) KDM4CKDM6BALDH1A1KDM4ETDP1
SCHEMBL4768904 0.98 KDM4C (0.53) KDM4CKDM6BALDH1A1KDM4ETDP1
SCHEMBL11819131 0.89 KDM4C (0.46) KDM4CKDM6BALDH1A1KDM4ETDP1
SCHEMBL27711603 0.84 KDM4C (0.42) KDM4CKDM6BALDH1A1KDM4ETDP1
SCHEMBL2562774 0.82 KDM4C (0.61) KDM4CKDM6BALDH1A1KDM4ETDP1
SCHEMBL29822292 0.82 KDM4C (0.61) KDM4CKDM6BALDH1A1KDM4ETDP1
SCHEMBL29416303 0.81 KDM4C (0.65) KDM4CKDM6BALDH1A1KDM4ETDP1
SCHEMBL71335 0.81 KDM4C (0.65) KDM4CKDM6BALDH1A1KDM4ETDP1
SCHEMBL18163749 0.81 KDM4E (0.53) KDM4CALDH1A1KDM4ETDP1MEN1
SCHEMBL19838598 0.80 TDP1 (0.47) KDM4CKDM6BALDH1A1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12077680-B2 Polishing composition, production method of the same, polishing method and a manufacturing method of a semiconductor substrate FUJIMI INCORPORATED (JP) 2024-09-03 US claimed
CN-110759860-B Preparation method of 3-methyl formate-4-methoxy-5-cyanopyridine 江苏瑞科医药科技有限公司 2022-10-14 CN claimed
US-20210301174-A1 POLISHING COMPOSITION, PRODUCTION METHOD OF THE SAME, POLISHING METHOD AND A MANUFACTURING METHOD OF A SEMICONDUCTOR SUBSTRATE FUJIMI INCORPORATED (JP) 2021-09-30 US claimed
CN-110759860-A Preparation method of 3-methyl formate-4-methoxy-5-cyanopyridine 江苏瑞科医药科技有限公司 2020-02-07 CN claimed
US-9901663-B2 Hollow stent filled with a therapeutic agent formulation ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) 2018-02-27 US claimed
US-20170281653-A1 DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOKINES GREENPHARMA SAS (FR) 2017-10-05 US claimed
EP-2994174-A1 A HOLLOW STENT FILLED WITH A THERAPEUTIC AGENT FORMULATION Abbott Cardiovascular Systems Inc. (US) 2016-03-16 EP claimed
CN-105188791-A Hollow stent filled with therapeutic agent formulation ABBOTT CARDIOVASCULAR SYSTEMS 2015-12-23 CN claimed
WO-2014182542-A1 A HOLLOW STENT FILLED WITH A THERAPEUTIC AGENT FORMULATION ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) 2014-11-13 WO claimed
US-20140330365-A1 Hollow Stent Filled With A Therapeutic Agent Formulation ABBOTT CARDIOVASCULAR SYSTEMS INC. 2014-11-06 US claimed
EP-1183327-A1 METAL CHELATING FILTERS AND METAL CHELATE FILTERS Panbio Ltd. (AU) 2002-03-06 EP claimed
WO-2000070012-A1 METAL CHELATING FILTERS AND METAL CHELATE FILTERS PANBIO LTD (AU) 2000-11-23 WO claimed
US-5430049-A Treating hyperproliferative disorders GAUT ZANE N (US) 1995-07-04 US claimed
EP-0064378-B1 AFFINITY CHROMATOGRAPHY USING METAL IONS The Public Health Laboratory Service Board (GB) 1987-02-11 EP claimed
US-4431546-A SEPARATION OF BIOLOGICAL MATERIAL IN A SOLUTION CONTAINING A METAL SALT USING A MATRIX-DYE LIGAND THE PUBLIC HEALTH LABORATORY SERVICES BOARD (GB) 1984-02-14 US claimed
EP-0064378-A2 Affinity chromatography using metal ions The Public Health Laboratory Service Board (GB) 1982-11-10 EP claimed
JP-63105027-A None JP disclosed
JP-9148195-A None JP disclosed
US-3945995-A ANTIBIOTICS, PENICILLIN SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1976-03-23 US disclosed
US-3939150-A ALPHA-(4-OXO-4H-THIOPYRAN-3-CARBOXAMIDO)-P-HYDROXYBENZYL -PENICILLIN OR SALTS, BACTERICIDE YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) 1976-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281653-A1 DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOKINES CCL2, CCL11, CCL5 KDM4C 4324/4885KDM6B 3517/4885ALDH1A1 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.